DATE: January 15, 2019

TIME:  4:00pm SGT

There is a clear call to automate manufacturing for cell and gene therapy products, but when should you automate? In this session, we will consider the shifting priorities as you move from product development towards clinical manufacturing and discuss how choosing the right type of automation can create immediate impact without compromising flexibility. Case studies in adherent and suspension cell expansion, gene modification and cell secretome production will be presented.

Who may be interested:

• Clinicians, researchers, lab technologists and cell therapy industry professional
• Cell and gene therapy manufacturing professionals
• Contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs)

Key learning objectives:

• Understand the impact of Investigational New Drug submission on the manufacturing process
• Learn how various adopters of the Quantum^® Cell Expansion System have improved their manufacturing processes